What Is PT-141 (Bremelanotide)? A Research Overview

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide classified as a melanocortin receptor agonist and studied in receptor-signaling research. The material described here is supplied strictly for controlled in-vitro laboratory research by qualified professionals. It is not a finished pharmaceutical product and is not for human or veterinary use.

Quick facts

• Class: melanocortin receptor agonist (activity at MC4R and other melanocortin receptor subtypes)
• Research focus: melanocortin-system signaling research
• Identity: synthetic cyclic heptapeptide; also known as bremelanotide
• Form: lyophilized powder for laboratory research use only

What is PT-141?

PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide derived from the melanocortin peptide family. Scientific literature describes its molecular structure and melanocortin-receptor activity. Bolt Peptide material is a research-use-only reference compound for controlled laboratory study.

What does the research show?

Published sources characterize bremelanotide across controlled receptor, pharmacokinetic, and investigational studies [1][2][3]. These citations are included only to document nomenclature, mechanism, and the scientific record; they do not provide a route, amount, protocol, or expected outcome for any Bolt material.

Mechanisms studied in the lab

• Melanocortin receptor agonism: experimental literature describes nonselective activation of melanocortin receptor subtypes, including binding observations at MC1R and MC4R.
• Central nervous system signaling: MC4R-expressing neurons are distributed across many regions of the central nervous system, and melanocortin-system signaling in the CNS is a focus of mechanistic research on this compound.

Research status and safety

PT-141 supplied by Bolt Peptide is intended exclusively for controlled in-vitro and analytical laboratory investigation by qualified researchers. It is not a finished pharmaceutical product and is not for human or veterinary use or consumption.

Handling

PT-141 is supplied in lyophilized form and should be managed according to the product documentation and the laboratory’s approved SOP. See the laboratory concentration and handling reference, browse the research catalog, or review PT-141 product details.

FAQ

Is Bolt Peptide PT-141 a finished commercial product? No. It is a research-use-only reference compound for controlled laboratory study.

What class of compound is PT-141? It is a synthetic cyclic heptapeptide classified as a melanocortin receptor agonist, with reported activity at melanocortin receptors including MC4R.

What is the intended context for PT-141? Controlled in-vitro laboratory research by qualified professionals only. It is not for human or veterinary use.

References

1. Diamond LE, et al. Evaluation of intranasal PT-141, a melanocortin receptor agonist. Int J Impot Res. 2004.
2. Kingsberg SA, et al. Bremelanotide: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019.
3. VYLEESI (bremelanotide) prescribing information. FDA / DailyMed. 2019.

For research use only. Not for human or veterinary use. The research material is not the FDA-approved medicine. Statements have not been evaluated by the FDA.